Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 27

Results For "commercialization"

350 News Found

AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer
People | March 07, 2022

AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer

Dr. Bibikova is an international leader with over 25 years of experience in genomics industry


Aquestive Therapeutics and Haisco Pharmaceutical partner for riluzole in China.
Biotech | March 06, 2022

Aquestive Therapeutics and Haisco Pharmaceutical partner for riluzole in China.

Around 85% of ALS patients suffer from a progressive loss of bulbar functionality


Alkem licenses technology from Harvard to treat ischemic injury and vascular diseases
Biotech | March 03, 2022

Alkem licenses technology from Harvard to treat ischemic injury and vascular diseases

Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy


SeQuent Scientific completes acquisition of Nourrie in Brazil
News | March 02, 2022

SeQuent Scientific completes acquisition of Nourrie in Brazil

Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%


IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines
Biotech | March 01, 2022

IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines

This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry


South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical
Biotech | March 01, 2022

South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical

Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical


HitGen completes research collaboration with MTPC
Biotech | February 27, 2022

HitGen completes research collaboration with MTPC

Collaboration with MTPC to discover novel hit compounds for multiple drug targets


Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb
Biotech | February 25, 2022

Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb

It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).


Aizon’s CEO John Vitalie named one of the top 25 Biotech CEOs of 2022
News | February 19, 2022

Aizon’s CEO John Vitalie named one of the top 25 Biotech CEOs of 2022

The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector


Quotient Sciences integrates drug substance into Translational Pharmaceutics Platform
Biotech | February 18, 2022

Quotient Sciences integrates drug substance into Translational Pharmaceutics Platform

The newly enhanced drug development platform will help empower innovators with the fastest development timelines